1 / 12

About the study

“Australia is #1 site to conduct clinical trials” Summary of Economist Intelligence Unit Report: Benchmarking Study of the Characteristics of the Australian and International Pharmaceutical Industries Sep 2005. About the study. Independent study conducted by Economist Intelligence Unit

adena-cantrell
Download Presentation

About the study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. “Australia is #1 site to conduct clinical trials”Summary of Economist Intelligence Unit Report: Benchmarking Study of the Characteristics of the Australian and International Pharmaceutical IndustriesSep 2005

  2. About the study • Independent study conducted by Economist Intelligence Unit • Commissioned by Australian Govt. Dept. Industry Tourism & Resources, Invest Australia, Victorian Govt. Dep. Innovation, Industry & Regional Development • Benchmarked Australian Industry versus: • USA • UK • Germany • Japan • Singapore • India Full report available at: www.industry.gov.au

  3. Summary Scores Across Pharmaceutical Industry

  4. Clinical Trials Benchmarking Aggregate Benchmark Scores What is driving Australia’s performance?

  5. Driven by low average cost per patient and high availability of research sites… Average cost per patient # sites per 100,000 pop. $6,712 (USA) to $2,500 (India) $3,984 (Australia) 25,000 (USA) to 11 (Singapore) 2,500 (Australia) source: CentreWatch

  6. …Good participation rates andhigh on-time completion rates… # patients in trials per 100,000 pop. % Studies completed on time 3,600,000 (USA) to 3,745 (India) 20,000 (Australia) 85% (India) to 10%(USA) 80% (Australia) source: CentreWatch

  7. …with a capacity to do more... #Phase I per 100,000 pop. #Phase II per 100,000 pop. #Phase III per 100,000 pop. #Other Phase per 100,000 pop. Other includes Phase IV, medical device, bioequivalence

  8. …and a quality workforce Pharma Industry skilled professionals per 100,000 LF. #Graduate degrees per 100,000 LF. Regulatory & Quality Systems Govt. Initiatives & Incentives Other includes Phase IV, medical device, bioequivalence

  9. Clinical Trial Activity 2004 2005

  10. Snapshot of Australian Pharma & Biotechnology Industry • Pharma company sales in Australia $6b (1.2% of world market) • 93% prescription sales covered under PBS (Govt. funded) • 57% having some degree of local manufacture • Export sales of Pharmaceuticals $2.4b • 421 Core biotechnology companies (83 listed) • Market cap $4.3b (ex. CSL) • 612 Medical device companies (45 listed) • Market cap $9.0b Source: Bioindustry Review 2006

  11. Australian Biotech sector is very active in forming alliances 28% Internal 36% North America 2% Africa 3% NZ/Pacific 12% Asia 19% Europe • 112 alliances formed with US companies in 2005 • Australian Biotechs purchased 24 overseas companies Source: Bioindustry Review 2006

  12. Key Takeaways: • Australia is an excellent location for conducting clinical research • Australia has a vibrant Biotech & pharmaceutical sector • Australian companies want to work with international partners

More Related